Reinventing the fight against bacteria,
one phage at a time.

Recurrent urinary tract infections remain one of the most persistent bacterial diseases worldwide, affecting an estimated 400 to 450 million people every year and generating billions of euros in healthcare costs. In Europe alone, urinary tract infections account for more than 10 million medical consultations annually, with a significant proportion involving recurrent cases. These infections disproportionately affect women, with nearly 50 to 60 percent experiencing at least one episode during their lifetime and up to 30 percent developing recurrent infections.  © The Phage Therapy A major European initiative hopes to change this landscape. The REPhRAME project, coordinated by Universitätsmedizin Frankfurt under the leadership of Professor Maria J.G.T. Vehreschild, has secured €15 million through the Horizon Europe research programme to evaluate an entirely new therapeutic strategy. Running over five years from June 2026, the project will conduct the first randomized clinical trial i...

For several years now, the Hospices Civils de Lyon have occupied a special place in the revival of phage therapy in Western Europe. While interest in bacteriophages has increased worldwide as antimicrobial resistance continues to spread, the teams in Lyon have pursued an objective that extends beyond clinical experimentation. Their ambition has been to reconstruct an entire therapeutic phage ecosystem, from the isolation of phages in the environment to the production of pharmaceutical-grade preparations suitable for human administration. © Hospices Civils de Lyon This long-term effort reached an important milestone in May 2026, when the French National Agency for Medicines and Health Products Safety granted the Hospices Civils de Lyon authorization to manufacture therapeutic phages as pharmaceutical starting materials intended for human use. The authorization concerns both the production of phage intermediates and purified therapeutic preparations produced according to Good Manufacturi...

For many years, the relationship between bacteriophages and bacteria was largely viewed as a straightforward arms race in which viruses infect bacterial cells while hosts evolve increasingly sophisticated defense systems to resist invasion. Recent discoveries, however, reveal a far more intricate biological dialogue. Viruses are not merely passive invaders that exploit cellular machinery. They are capable of rewiring bacterial signaling pathways, manipulating intracellular messengers and reshaping regulatory networks to favor their own persistence. A striking example of this remarkable strategy has now been uncovered in Acinetobacter baumannii, one of the most problematic multidrug resistant pathogens encountered in modern hospitals. © The Phage Therapy Researchers have discovered that this bacterium naturally produces a class of signaling molecules known as 2′,3′ cyclic nucleotide monophosphates, or 2′,3′ cNMPs. Although related compounds have been extensively studied in plants, mamma...

For decades, bacteriophages have been portrayed as remarkably efficient yet relatively simple biological entities whose ecological role was largely understood through experiments involving a single bacterial host and a single virus. This reductionist view has generated invaluable knowledge about phage infection cycles, host resistance and molecular evolution, but it has also obscured the extraordinary complexity that emerges when viruses evolve inside natural microbial communities composed of hundreds of interacting species. A recent discovery is now forcing researchers to reconsider some of the most fundamental assumptions regarding viral ecology and evolution. © The Phage Therapy Scientists studying cellulose degrading microbial communities derived from garden compost have identified a previously unknown bacteriophage that reached an unprecedented level of dominance within its ecosystem. This virus, named Theomophage, was capable of accounting for more than seventy percent of all met...

For more than a century, bacteriophages have been described as remarkably efficient yet fundamentally simple biological machines. Their compact genomes, streamlined replication cycles and intimate dependence on bacterial hosts seemed to define the limits of viral complexity. The discovery and characterization of jumbo phages have profoundly changed this view. These viral giants, carrying genomes larger than 200 kilobases and sometimes exceeding 700 kilobases, reveal a degree of organization that few scientists would have imagined possible in bacteriophages. © The Phage Therapy The term "jumbo phage" may sound like a simple reference to genome size, but it encompasses a remarkable diversity of viral strategies. Some of these phages possess genomes larger than those of many bacteria and encode hundreds of proteins, a significant fraction of which still have no known function. Their virions are equally impressive. The giant bacteriophage G, for example, possesses a capsid nearly...

As antimicrobial resistance continues to rise worldwide, bacteriophage therapy is increasingly emerging as one of the most promising alternatives to conventional antibiotics. In Japan, biotechnology company Arrowsmith has recently announced two important milestones that illustrate the growing maturity of the field: the successful completion of a Series A financing round totaling 1.05 billion yen and the completion of a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration for its lead phage therapy candidate, ARW001. The Phage Therapy © The financing, equivalent to approximately 7.3 million US dollars, will primarily support the clinical development of ARW001, a therapeutic phage cocktail targeting Pseudomonas aeruginosa. This opportunistic Gram-negative bacterium is one of the most problematic hospital pathogens worldwide. It is responsible for severe respiratory infections, bloodstream infections, chronic wound infections and complications in patients with c...

The first years of life represent one of the most critical periods in human biological development. During this narrow window, the infant gut is progressively colonized by trillions of microorganisms that will influence metabolism, immune maturation, and long-term health. While bacteria have received most of the scientific attention, a parallel microbial world is developing alongside them: the gut virome. Dominated by bacteriophages, viruses that infect bacteria, this viral ecosystem has remained surprisingly elusive despite its enormous biological importance. © The Phage Therapy A new large-scale study published in Nature Communications now provides one of the most comprehensive portraits ever produced of the infant gut virome. By integrating data from 12 independent cohorts spanning eight countries and nearly one thousand healthy infants, researchers demonstrate that bacteriophage communities do not emerge randomly after birth. Instead, they follow a highly conserved developmental tr...